Fulcrum Therapeutics, Inc (FULC)

Etorro trading 970x250
Fulcrum Therapeutics, Inc (FULC) Logo

About Fulcrum Therapeutics, Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. Address: 26 Landsdowne Street, Cambridge, MA, United States, 02139

Fulcrum Therapeutics, Inc News and around…

Latest news about Fulcrum Therapeutics, Inc (FULC) common stock and company :

Analysts Anticipate XPH To Hit $69
18 Jan, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Pharmaceuticals ETF (XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $68.83 per unit.

Hedge Funds Are Crazy About Fulcrum Therapeutics, Inc. (FULC)
12 Jan, 2022 Yahoo! Finance

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases
10 Jan, 2022 Yahoo! Finance

First patient dosed in Phase 1b trial of FTX-6058 in sickle cell disease; Initial data expected in 2Q 2022 Submitted IND for FTX-6058 to support initiation of Phase 1b trial in select hemoglobinopathies in 2Q 2022 On track to provide update on losmapimod in FSHD in 1Q 2022 Kate Haviland appointed Chair of board of directors CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of pa

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jan, 2022 Yahoo! Finance

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the grant of an inducement award outside of the Company’s 2019 Stock Incentive Plan to Esther Rajavelu, the Company’s newly appointed Chief Financial Officer. The grant was approved by a majority of the independent directors of the Company on January 3, 2022 as a

Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference
06 Jan, 2022 Yahoo! Finance

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Bryan Stuart, President and Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 12:00 p.m. ET. A live audio webcast will be available through the Investor Relations section of th

Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer
04 Jan, 2022 Yahoo! Finance

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Esther Rajavelu as Chief Financial Officer. Ms. Rajavelu brings nearly 20 years of experience in the life sciences sector spanning equities research, investment banking and strategic consulting. She will be responsible for overseeing Fulcrum’s

Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ...
23 Dec, 2021 Yahoo! Finance

Investment company Rtw Investments, Lp (Current Portfolio) buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, argenx SE, Macrogenics Inc, sells Quidel Corp, Protagonist Therapeutics Inc, MiMedx Group Inc, , Castle Biosciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Rtw Investments, Lp.

Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...
21 Dec, 2021 Yahoo! Finance

Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Corp, , Agenus Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Boxer Capital, Llc.

Analysts See 15% Gains Ahead For The Holdings of TUSA
14 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Total US Market AlphaDEX ETF (TUSA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $56.82 per unit.

We're Hopeful That Fulcrum Therapeutics (NASDAQ:FULC) Will Use Its Cash Wisely
14 Dec, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Fulcrum Therapeutics Breaks Above 200-Day Moving Average - Bullish for FULC
07 Dec, 2021 FinancialContent

In trading on Tuesday, shares of Fulcrum Therapeutics Inc (FULC) crossed above their 200 day moving average of $15.73, changing hands as high as $15.93 per share. Fulcrum Therapeutics Inc shares are currently trading up about 9.9% on the day..

Fulcrum Therapeutics Shares Additional Data From Phase 1 Trial Of Sickle Cell Disease Treatment
06 Dec, 2021 FinancialContent

Fulcrum Therapeutics Inc(NASDAQ: FULC) has announcedresults from the 20mg and 30mg dose cohortsin healthy adult ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
06 Dec, 2021 FinancialContent

Gainers Adicet Bio (NASDAQ:ACET) stock increased by 37.85% to $13.51 during Monday's pre-market session. The market ...

Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data
06 Dec, 2021 Yahoo! Finance

Achieved mean 5.6-fold HBG mRNA induction at 20mg and mean 6.2-fold at 30mg after 14 days of once-daily dosing, further supporting potential of FTX-6058 to provide a functional cure Continues to be well-tolerated at higher doses with no serious adverse events observed to date New mechanism data demonstrate potent downregulation of BCL11A and MYB, key repressors of fetal hemoglobin On track to initiate enrollment in Phase 1b clinical trial in people with sickle cell disease and to submit an IND f

Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors
17 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Sonja L. Banks to the company’s board of directors, effective December 8. Ms. Banks is currently the chief executive officer of the International Dyslexia Association and was formerly president of the Sickle Cell Disease Association of America

Analysts Expect 14% Upside For PTH
12 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA Healthcare Momentum ETF (PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $185.19 per unit.

Investors Snag FULC Even Cheaper Than Its Secondary Stock Offering
04 Nov, 2021 FinancialContent

Looking back to 85 days ago, Fulcrum Therapeutics Inc (FULC) priced a 6,600,000 share secondary stock offering at $19.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

Fulcrum Therapeutics, Inc. (FULC) Reports Q3 Loss, Tops Revenue Estimates
04 Nov, 2021 Yahoo! Finance

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 10.94% and 68.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
04 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral ...

Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results
04 Nov, 2021 Yahoo! Finance

–On-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease– – Losmapimod update planned for Q1 2022 – –Raised $144.2 million in gross proceeds from August 2021 public offering, extending cash runway into 2024 – – Conference call scheduled for 8:00 a.m. ET today – CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of pati

Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences
03 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in the following upcoming investor conferences: Credit Suisse 30th Annual Virtual Healthcare ConferenceThursday, November 11, 2021 at 4:20pm ET Stifel Virtual Healthcare ConferenceWednesday, November 17, 2021 at 11:20am ET Pi

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct, 2021 FinancialContent

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly ...

Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8:00 a.m. ET
28 Oct, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2021 financial results will be released on Thursday, November 4, 2021 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporat

Can Fulcrum Therapeutics, Inc. (FULC) Climb 31% to Reach the Level Wall Street Analysts Expect?
14 Oct, 2021 Yahoo! Finance

The consensus price target hints at a 30.9% upside potential for Fulcrum Therapeutics, Inc. (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Analysts Expect PTH Will Reach $181
07 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA Healthcare Momentum ETF (PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $180.51 per unit.

Fulcrum Therapeutics's Return On Capital Employed Overview
22 Sep, 2021 FinancialContent

Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q2 sales of $4.38 million. Earnings fell to a loss of $19.68 million, ...

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
22 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Shares Of Fulcrum Therapeutics Inc. Rise Above Previous 52-Week High
21 Sep, 2021 Yahoo! Finance

Shares of Fulcrum Therapeutics Inc. (NASDAQ: FULC) traded today at $33.00, eclipsing its 52-week high. Approximately 12.2 million shares have changed hands today, as compared to an average 30-day volume of 7 million shares. Fulcrum Therapeutics Inc. share prices have moved between a 52-week high of $33.00 and a 52-week low of $6.85 and are now trading 367% above that low price at $32.00 per share. Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It has developed a proprie

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society
20 Sep, 2021 FinancialContent

Fulcrum Therapeutics, Inc (FULC) is a NASDAQ Common Stock listed in , ,

970x250